Literature DB >> 3038002

Adrenal response to corticotropin during therapy with itraconazole.

P Phillips, J R Graybill, R Fetchick, J F Dunn.   

Abstract

Itraconazole is a triazole with a mechanism of action similar to that of ketoconazole. Endocrine side effects of ketoconazole, including impaired cortisol synthesis, have been well documented (A. Pont, J. R. Graybill, P. C. Craven, J. N. Galgiani, W. E. Dismukes, R. E. Reitz, and D. A. Stevens, Arch. Intern. Med. 144:2150-2153, 1984). We examined the adrenal response to corticotropin in 10 patients being treated with itraconazole. No impairment of cortisol synthesis could be demonstrated.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3038002      PMCID： PMC174799          DOI： 10.1128/AAC.31.4.647

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells.

Authors:  J Kowal
Journal:  Endocrinology       Date:  1983-04       Impact factor: 4.736

2.  Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis.

Authors:  T Schürmeyer; E Nieschlag
Journal:  Acta Endocrinol (Copenh)       Date:  1984-02

3.  Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia.

Authors:  A Pont; E S Goldman; A M Sugar; P K Siiteri; D A Stevens
Journal:  Arch Intern Med       Date:  1985-08

4.  Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

Authors:  W E Dismukes; A M Stamm; J R Graybill; P C Craven; D A Stevens; R L Stiller; G A Sarosi; G Medoff; C R Gregg; H A Gallis; B T Fields; R L Marier; T A Kerkering; L G Kaplowitz; G Cloud; C Bowles; S Shadomy
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

5.  Ketoconazole blocks testosterone synthesis.

Authors:  A Pont; P L Williams; S Azhar; R E Reitz; C Bochra; E R Smith; D A Stevens
Journal:  Arch Intern Med       Date:  1982-11

6.  Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.

Authors:  J H Lewis; H J Zimmerman; G D Benson; K G Ishak
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

7.  Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.

Authors:  D S Loose; P B Kan; M A Hirst; R A Marcus; D Feldman
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

8.  Site of action of low dose ketoconazole on androgen biosynthesis in men.

Authors:  R J Santen; H Van den Bossche; J Symoens; J Brugmans; R DeCoster
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

9.  Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins.

Authors:  D S Grosso; T W Boyden; R W Pamenter; D G Johnson; D A Stevens; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

10.  Gynecomastia with ketoconazole.

Authors:  R DeFelice; D G Johnson; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191
View more
  9 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  High-dose itraconazole in the treatment of severe mycoses.

Authors:  P K Sharkey; M G Rinaldi; J F Dunn; T C Hardin; R J Fetchick; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Itraconazole: Precautions regarding drug interactions and bioavailability.

Authors:  M P Puttick; P Phillips
Journal:  Can J Infect Dis       Date:  1994-07

4.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.

Authors:  B Lebrun-Vignes; V C Archer; B Diquet; J C Levron; O Chosidow; A J Puech; D Warot
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

5.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 6.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 7.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 8.  New antifungal agents.

Authors:  J R Graybill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

9.  Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients.

Authors:  Shelley S Magill; Thanyawee Puthanakit; Sandra M Swoboda; Kathryn A Carson; Roberto Salvatori; Pamela A Lipsett; Craig W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.